Selected article for: "early outbreak and Hubei province"

Author: Azer, Samy A.
Title: COVID-19: Pathophysiology, diagnosis, complications and Investigational therapeutics
  • Cord-id: ja96xfns
  • Document date: 2020_8_5
  • ID: ja96xfns
    Snippet: Abstract The novel coronavirus (COVID-19) outbreak started early in December 2019 in the Hubei province and its capital Wuhan of the People’s Republic of China and caused a global pandemic. The number of patients confined to this disease has exceeded nine million in more than 215 countries, and the number who died is over 480,600 (up to 25 June 2020). Coronaviruses were identified in the 1960s and recently identified to cause the Middle East Respiratory Syndrome (MERS-CoV) in 2012 and severe a
    Document: Abstract The novel coronavirus (COVID-19) outbreak started early in December 2019 in the Hubei province and its capital Wuhan of the People’s Republic of China and caused a global pandemic. The number of patients confined to this disease has exceeded nine million in more than 215 countries, and the number who died is over 480,600 (up to 25 June 2020). Coronaviruses were identified in the 1960s and recently identified to cause the Middle East Respiratory Syndrome (MERS-CoV) in 2012 and severe acute respiratory syndrome (SARS) in 2003. The current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the most recently identified. Patients with COVID-19 may be asymptomatic. Typical symptoms including fever, dry cough, and shortness of breath. Gastrointestinal symptoms such as nausea, vomiting, abdominal pain and diarrhea, have been reported—neurologically related symptoms, particularly anosmia, hyposmia, and dysgeusia, have also been reported. Physical examination may reveal a fever in over 44% of patients (and could be documented in over 88% of patients after admission), increased respiratory rate, acute respiratory disease, and maybe decreased consciousness, agitation, and confusion. This article aims at presenting an up-to-date review on the pathogenesis, diagnosis and complications of COVID-19 infection. Currently, no therapeutics have been found to be effective. Investigational therapeutics are briefly discussed.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and lymphocyte ratio: 1, 2, 3, 4, 5
    • abdominal pain vomiting and lymphocyte ratio: 1, 2, 3
    • abdominal pain vomiting nausea and lymphocyte ratio: 1
    • abdominal pain vomiting nausea diarrhea and lymphocyte ratio: 1
    • acute coronary syndrome and lymphocyte ratio: 1, 2
    • acute coronary syndrome heart failure and lymphocyte ratio: 1, 2
    • acute myocardial injury and lymphocyte ratio: 1, 2, 3
    • acute respiratory distress syndrome and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and lung pathology: 1, 2, 3, 4, 5, 6
    • acute respiratory failure and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • liver disease and lung pathology: 1, 2
    • liver disease and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • liver injury and lung pathology: 1
    • liver injury and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • lung heart and lymphocyte ratio: 1, 2, 3, 4
    • lung injury and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lung pathology and lymphocyte ratio: 1